10-KPeriod: FY2022

Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2022

Filed February 13, 2023For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) reported its 2022 full-year results, demonstrating resilience despite prevailing macroeconomic challenges and the lingering effects of the COVID-19 pandemic. The company achieved net sales of $5.4 billion, a 2.9% increase year-over-year, driven primarily by strong performance in its Transcatheter Aortic Valve Replacement (TAVR) segment, which represented 65% of total net sales. The company continues to invest heavily in research and development, with R&D expenses increasing by 5% year-over-year, representing 18% of sales, focusing on next-generation TAVR technologies and expanding its Transcatheter Mitral and Tricuspid Therapies (TMTT) offerings. Despite foreign currency headwinds that impacted international sales by $140.2 million, Edwards Lifesciences maintained effective foreign currency hedging programs, contributing to a gross profit increase. The company also saw growth in its Surgical Structural Heart and Critical Care segments. Management highlighted key regulatory approvals and product launches in 2022, including FDA approval for the MITRIS RESILIA valve and PASCAL Precision system, and the launch of the SAPIEN 3 Ultra RESILIA valve in the U.S. While the company is navigating various risks, including regulatory compliance, competition, and supply chain considerations, its strategic focus on innovation and patient-centric solutions positions it for continued leadership in the structural heart disease and critical care monitoring markets.

Financial Highlights

54 data points
Beta

Revenue

$4.46B

83.8% Gross Margin

Net Income

$1.52B

34.1% Net Margin

EPS (Diluted)

$2.44

Total Assets

$8.29B

Cash & Equivalents

$772.60M

Free Cash Flow

$973.60M

Financial Statements
Beta
Revenue$4.46B
Cost of Revenue$723.70M
Gross Profit$3.74B
R&D Expenses$843.60M
SG&A Expenses$1.36B
Operating Income$1.50B
Interest Expense$19.20M
Net Income$1.52B
EPS (Basic)$2.46
EPS (Diluted)$2.44
Shares Outstanding (Basic)619.00M
Shares Outstanding (Diluted)624.20M

Key Highlights

  • 1Net sales for 2022 reached $5.4 billion, an increase of 2.9% compared to 2021, primarily driven by the TAVR segment.
  • 2The company invested 17.6% of its net sales in R&D during 2022, signaling a strong commitment to innovation, particularly in TAVR and TMTT.
  • 3Key product advancements in 2022 included FDA approval for the MITRIS RESILIA valve and PASCAL Precision system, and the U.S. launch of the SAPIEN 3 Ultra RESILIA valve.
  • 4Despite foreign currency headwinds negatively impacting international sales by $140.2 million, the company's hedging programs helped offset some of these effects.
  • 5The company repurchased $1.7 billion of its common stock in 2022, demonstrating a commitment to returning capital to shareholders.
  • 6Operating income for 2022 was $1.75 billion, reflecting a slight increase from the prior year, despite increased SG&A and R&D expenses.

Frequently Asked Questions

The primary driver of net sales growth in 2022 was the continued strong performance of the Transcatheter Aortic Valve Replacement (TAVR) segment, particularly the Edwards SAPIEN platform, which saw increased sales in the United States, Europe, and Rest of World markets. Growth was also supported by the Surgical Structural Heart and Critical Care segments.

Foreign currency exchange rate fluctuations negatively impacted net sales by $140.2 million in 2022, primarily due to the weakening of the Euro and Japanese yen against the U.S. dollar. However, the company's foreign currency hedging program helped to mitigate some of these effects on gross profit.

Edwards Lifesciences significantly invests in R&D, with 17.6% of net sales dedicated to this in 2022. Key focus areas include developing new products and enhancing existing ones within the Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments, as well as advancing decision support solutions for its Critical Care product line.

Edwards Lifesciences has never paid cash dividends and currently plans to retain earnings for business reinvestment. The company actively engages in share repurchases, having repurchased $1.7 billion of its common stock in 2022, as part of an ongoing program authorized by its Board of Directors.

Key risks and challenges identified include the ability to innovate and market new products successfully, potential issues in clinical trials or procedures, manufacturing and quality control, public health crises, intense competition, reliance on third-party suppliers, and the impact of government regulations and reimbursement policies. Intellectual property protection and cybersecurity are also noted as critical risk areas.